Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02579239 · ClinicalTrials.gov registry record · Phase 1
Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)
A Phase 1 study, sponsored by aTyr Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02579239 is a Phase 1 study that has completed, run by aTyr Pharma. The registered enrollment target is 18 participants.
The verdict
NCT02579239, a Phase 1 study, has completed, sponsored by aTyr Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and biological activity of ATYR1940 in participants with LGMD2B and FSHD.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL ATYR1940
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-11-30 |
| Est. Completion | 2016-10-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02579239
The ClinicalTrials.gov registry entry for NCT02579239 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is aTyr Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02579239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02579239 about?
NCT02579239 is a clinical study titled "Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)". The purpose of this study is to assess the safety and biological activity of ATYR1940 in participants with LGMD2B and FSHD.
What is the current status of trial NCT02579239?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2015-11-30. Estimated completion is 2016-10-05.
What interventions are being tested in trial NCT02579239?
The interventions under investigation include: Placebo (BIOLOGICAL), ATYR1940 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02579239?
This trial is sponsored by aTyr Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.